New combo tackles tough colorectal cancer in small trial
NCT ID NCT03828799
First seen Feb 28, 2026 · Last updated May 24, 2026 · Updated 15 times
Summary
This early-phase study tested a combination of two treatments—regorafenib and FOLFIRINOX chemotherapy—in 13 people with advanced colorectal cancer that has a specific gene change (RAS mutation). The main goal was to see if the combination is safe and tolerable. Researchers also looked at how long the cancer stayed under control. This is not a cure, but a way to manage the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Antoine Lacassagne
Nice, Alpes-Maritimes, 06189, France
-
Centre Cario - HPCA
Plérin, Finistère, 22190, France
-
Centre Georges-François Leclerc
Dijon, Côte d'Or, 21079, France
-
Institut du Cancer de Montpellier - Val d'Aurelle
Montpellier, 34298, France
Conditions
Explore the condition pages connected to this study.